Antipsychotics and diabetes: An age-related association

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1316-1322

  Hammerman, Ariel ^a   Dreiher, Jacob ^b   Klang, Shmuel H ^a   Munitz, Hanan ^a   Cohen, Arnon D ^a   Goldfracht, Margalit ^c  

^a CLALIT HEALTH SERVICES   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Department of Quality Improvement

Author keywords

Antipsychotics; Diabetes; Neuroleptics; Pharmacoepidemiology; Psychosis; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; INFANT; ISRAEL; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 50249163625     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L015     Document Type: Article

References (35)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
2. Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 2004;19:1200-5.
3. Koro CE, Fedder DO, L'Italien GJ. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243-7.
4. Dunlop BW, Sternberg M, Phillips LS, Andersen J, Duncan E. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull 2003;37:99-117.
5. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. A frequently sampled intravenous tolerance test and minimal model analysis. Arch Gen Psychiatry 2006;62:19-28.
6. Newcomer JW. Antipsychotic medications: metabolism and cardiovascular risk. J Clin Psychiatry 2007;68(suppl 4):8-13.
7. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 23):30-8.
8. Lean MEJ, Pajonk FG. Patients on atypical antipsychotic drugs; another high-risk group for type 2 diabetes. Diabetes Care 2003;26:1597-605.
9. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 2005;8:183-94.
10. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
11. Citrome L. Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus. Int J Neuropsychopharmacol 2005;8:147-51.
12. Rettenbacher MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry 2005;18:175-9.
13. L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007;68:1510-6.
14. DuMouchel W, Fram D, Yang X, et al. Antipsychotics, glycemic disorders, and life-threatening events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Ann Clin Psychiatry 2008;20:21-31.
15. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008;101:273-86. DOI 10.1016/j.schres.2007.12.487
16. Sacher J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008;33:1633-41. DOI 10.1038/sj.npp.1301541
17. Peuskens J, De Hert M, Mortimer A; SOLIANOL Study Group. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007;22:145-52.
18. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81.
19. Hung CF, Wu CK, Lin PY. Diabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry 2005;29: 523-7.
20. Lamberti J, Crilly J, Maharaj K, Olson D, Costea O. Prevalence of adult-onset diabetes among outpatients receiving antipsychotic drugs (abstract). Schizophr Res 2003;60:S360.
21. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
22. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48:345-7.
23. Holt RIG, Peveler RC. Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia 2006;49:1467-76.
24. Cohen D, Dekker JJ, Peen J, Gispen-de Wied CC. Prevalence of diabetes mellitus in chronic schizophrenia inpatients in relation to long-term antipsychotic treatment. Eur Neuropsychopharmacol 2006;16:187-94.
25. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
26. McCreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia. Br J Psychiatry 2003;183:534-9.
27. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang R, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2003;63:920-30.
28. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63:1135-9.
29. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037-43.
30. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58:1172-6.
31. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003;23:1411-5.
32. Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005;193:387-95.
33. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
34. Gianfrancesco F, Wang RH, Nasrallah HA. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Ann Clin Psychiatry 2006;18:9-17.
35. Tshomer A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007;61:1356-70.